Skip to main content
NCBI home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 1995 May;4(3):209–216. doi: 10.1155/S0962935195000342

Analysis of the IFN-γ-induced signal transduction pathway in fetal rejection

Irene Athanassakis 1
PMCID: PMC2365634  PMID: 18475641

Abstract

The placenta, one of the most important fetal tissues during gestation, ensures nutrition, development and protection of the fetus. Although placenta lacks expression of class II MHC antigens, they can be induced either by interferon-gamma (IFN-γ) on the spongiotrophoblast zone, or by 5-azacytidine (5-azaC) on the labyrinthine trophoblast zone, two agents actively participating in a plethora of immunological and inflammatory reactions. This induction is correlated with fetal abortion and fetal developmental abnormalities. In this work the in vitro and in vivo signal transduction pathways followed by IFN-γ or 5-azaC to induce class H antigen expression on placental cells by using specific pathway inhibitors has been studied. It is shown that at least three intracellular pathways are implicated in the Ia induction, p21ras is the first protein activated by the two agents while further signalling requires Ca2+ mobilization and PKC activations. When the in vitro results are transferred to live animals using the same inducing agents and pathway inhibitors, it is found that theophylline (Ca2+/CaM inhibitor) and anti-p21ras are the most potent suppressors of the IFN-γ- and 5-azaC-induced side effects during pregnancy. The data presented here point to novel directions not only as to the intracellular signalling, but also to the use of pathway inhibitors in vivo to treat aberrant antigen expression associated with fetal loss.

Full Text

The Full Text of this article is available as a PDF (872.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benveniste E. N., Vidovic M., Panek R. B., Norris J. G., Reddy A. T., Benos D. J. Interferon-gamma-induced astrocyte class II major histocompatibility complex gene expression is associated with both protein kinase C activation and Na+ entry. J Biol Chem. 1991 Sep 25;266(27):18119–18126. [PubMed] [Google Scholar]
  2. Cohen P. Signal integration at the level of protein kinases, protein phosphatases and their substrates. Trends Biochem Sci. 1992 Oct;17(10):408–413. doi: 10.1016/0968-0004(92)90010-7. [DOI] [PubMed] [Google Scholar]
  3. Gumina R. J., Freire-Moar J., DeYoung L., Webb D. R., Devens B. H. Transduction of the IFN-gamma signal for HLA-DR expression in the promonocytic line THP-1 involves a late-acting PKC activity. Cell Immunol. 1991 Dec;138(2):265–279. doi: 10.1016/0008-8749(91)90152-2. [DOI] [PubMed] [Google Scholar]
  4. Hepler J. R., Gilman A. G. G proteins. Trends Biochem Sci. 1992 Oct;17(10):383–387. doi: 10.1016/0968-0004(92)90005-t. [DOI] [PubMed] [Google Scholar]
  5. Ina Y., Koide Y., Nezu N., Yoshida T. O. Regulation of HLA class II antigen expression: intracellular signaling molecules responsible for the regulation by IFN-gamma and cross-linking of Fc receptors in HL-60 cells. J Immunol. 1987 Sep 1;139(5):1711–1717. [PubMed] [Google Scholar]
  6. Liscovitch M. Crosstalk among multiple signal-activated phospholipases. Trends Biochem Sci. 1992 Oct;17(10):393–399. doi: 10.1016/0968-0004(92)90007-v. [DOI] [PubMed] [Google Scholar]
  7. Roullet J. B., Xue H., Pappu A. S., Roullet C., Holcomb S., McCarron D. A. Mevalonate availability and cardiovascular functions. Proc Natl Acad Sci U S A. 1993 Dec 15;90(24):11728–11732. doi: 10.1073/pnas.90.24.11728. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Schafer W. R., Kim R., Sterne R., Thorner J., Kim S. H., Rine J. Genetic and pharmacological suppression of oncogenic mutations in ras genes of yeast and humans. Science. 1989 Jul 28;245(4916):379–385. doi: 10.1126/science.2569235. [DOI] [PubMed] [Google Scholar]
  9. Scher M. G., Beller D. I., Unanue E. R. Demonstration of a soluble mediator that induces exudates rich in Ia-positive macrophages. J Exp Med. 1980 Dec 1;152(6):1684–1698. doi: 10.1084/jem.152.6.1684. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Steeg P. S., Moore R. N., Johnson H. M., Oppenheim J. J. Regulation of murine macrophage Ia antigen expression by a lymphokine with immune interferon activity. J Exp Med. 1982 Dec 1;156(6):1780–1793. doi: 10.1084/jem.156.6.1780. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Vassiliadis S., Athanassakis I. Type II interferon may be a potential hazardous therapeutic agent during pregnancy. Br J Haematol. 1992 Dec;82(4):782–783. doi: 10.1111/j.1365-2141.1992.tb06967.x. [DOI] [PubMed] [Google Scholar]
  12. Vassiliadis S., Kyrpides N., Stravopodis D., Grigoriou M., Athanassakis I., Papamatheakis J. Investigation of intracellular signals generated by gamma-interferon and IL-4 leading to the induction of class II antigen expression. Mediators Inflamm. 1993;2(5):343–348. doi: 10.1155/S096293519300047X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Vassiliadis S., Tsoukatos D., Athanassakis I. Interferon-induced class II expression at the spongiotrophoblastic zone of the murine placenta is linked to fetal rejection and developmental abnormalities. Acta Physiol Scand. 1994 Aug;151(4):485–495. doi: 10.1111/j.1748-1716.1994.tb09771.x. [DOI] [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES